Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
deepmirror logo — Step up your molecule discovery

deepmirror

Step up your molecule discovery

Founded 2019 United Kingdom London, United Kingdom 14 employees Pre Seed Biotechnology, Life Sciences

General Information

Company Name deepmirror
Founded Year 2019
Location United Kingdom London, United Kingdom +1
Employees 14
Industries Biotechnology, Life Sciences
Funding Stage Pre Seed
Social

Get notified when deepmirror moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

DeepMirror recently secured a Pre Seed round in July 2024, indicating continued investor confidence in its AI-powered drug discovery platform. This investment, paired with a significant website update (suggested by the data, likely a date anomaly), points towards a strategic refresh of its digital presence and product offering. These recent developments collectively position the company for accelerated growth and market engagement within the biopharmaceutical sector.

Signal Types
Funding Product Update
Strategic Labels
Early-Stage Funding Product Refresh Biotech Innovation
Next Move: Hiring
·
Impact: 8/10
·
Ideal For: AI Biotech VCs — Pre Seed

About deepmirror

deepmirror, founded in 2019, is revolutionizing drug discovery through its modern software specifically designed for chemists. With the goal to "Step up your molecule discovery," this UK-headquartered company operates primarily within the Biotechnology and Life Sciences industries.

The company recently attracted attention with its latest financing milestone being a Pre Seed Round investment on 31 July 2024, indicating early validation and interest in its innovative approach. This infusion of capital was led by bond-st, a noteworthy detail that highlights investor confidence in deepmirror's potential to enhance efficiency and innovation in drug design.

As deepmirror continues to develop its technology within this pivotal sector, prospective investors should focus on its ability to intersect cutting-edge software with biochemical advancements, positioning itself as a valuable contender capable of reshaping modern drug design landscapes.

Taxonomy: Molecule Discovery, Drug Design Software, Chemistry AI Platform, AI-Powered Drug Discovery, Deep Learning in Medicine, Data Science in Biology, AI in Chemistry, Biological Data Analysis, Machine Learning in Drug Development, Pharmaceutical Innovation, Image Analysis in Drug Discovery, AI-Enhanced Drug Candidates, Biotechnology Software

Services & Products

AI for hit-to-candidate molecule design
Data-driven potency and ADMET prediction
Generative AI for novel molecule discovery
Structure-guided design and hypothesis testing

Target Customers

Pharmaceutical Companies Biotech Startups Academic Researchers Medicinal Chemists Drug Discovery Teams

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round •••••• 1 •••• •••• 31 Jul 2024
Grant •••••• 1
Investor
14 Feb 2023
Pre Seed Round •••••• - 31 Aug 2022
Grant •••••• 1
Investor
01 Jul 2022

deepmirror Alternatives & Competitors

View All Alternatives
deepmirror vs
BioSolveIT
BioSolveIT Germany

expect actives!

33 employees
deepmirror vs
Synfini, Inc.
Synfini, Inc. United States

The Agile Drug Discovery Company

Unknown
14 employees
AI, Pharmaceutical
deepmirror vs
Ro5
Ro5 United Kingdom

Bioactivity. De Novo Drug Discovery. ADMET. Knowledge Graph.

Seed
12 employees
AI, Biotechnology
View all alternatives

FAQ About deepmirror

Step up your molecule discovery
deepmirror was founded in 2019.
deepmirror is headquartered in London, United Kingdom.
deepmirror operates in the following industries: Biotechnology, Life Sciences.
deepmirror has approximately 14 employees.
deepmirror has completed 4 funding rounds. The latest funding stage is Pre Seed.
deepmirror offers: AI for hit-to-candidate molecule design, Data-driven potency and ADMET prediction, Generative AI for novel molecule discovery, Structure-guided design and hypothesis testing.
Top alternatives and competitors to deepmirror include BioSolveIT, Synfini, Inc., Ro5, Deargen, X-37. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
deepmirror and BioSolveIT are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors deepmirror and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy